Tashkent, Uzbekistan (UzDaily.com) — New radiopharmaceutical "Rakurs (223Ra)" was registered in Russia.

The registration of this innovative drug will reduce logistical delays and improve access to this treatment method for Russian patients.

The Federal Medical-Biological Agency of Russia (FMBA) has obtained a registration certificate for the domestically produced radiopharmaceutical "Rakurs (223Ra)." This drug is used in radionuclide therapy for patients with castration-resistant prostate cancer with metastatic bone involvement.

The innovative product was developed at the Federal Scientific and Clinical Center for Medical Radiology and Oncology (FSCCMRO) of the FMBA in Dimitrovgrad, in collaboration with experts from the Research Institute of Atomic Reactors (JSC "RIAR," part of the scientific division of Rosatom State Corporation). The drug is based on locally sourced materials.

"For our team, this is another significant achievement in the field of nuclear medicine. In close cooperation with our colleagues from FSCCMRO, we have developed a drug with tremendous potential. Every stage of this collaborative effort required creative solutions and a combination of sound scientific ideas with excellent execution. We are moving in the right direction, and our partnership continues," stated Alexander Tuzov, Director of JSC RIAR.

"Rakurs" is a dual-action drug. Firstly, it destroys bone metastases, allowing individuals diagnosed with prostate cancer to extend their lives. The drug selectively accumulates in the bones, including bone metastases, resulting in a highly localized anti-tumor effect. Secondly, radium-223 alleviates pain syndromes, enabling patients to discontinue the use of pain-relieving medications, significantly enhancing their quality of life. The drug also shows potential for broader applications in treating metastatic bone lesions associated with other tumor localizations.

The collaboration between experts from the two scientific centers is ongoing, with additional radiopharmaceuticals under development by nuclear and medical specialists.